Esophageal Cancer Clinical Trials

71 studies are recruiting for esophageal cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

   RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patie…

   Stage

   Not phased

   Ages

   21 to 90

   Site

   University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT00900419 on ClinicalTrials.gov

2. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   5 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

3. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

   The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, LLC, Grand Rapids, Michigan

   Locations

   4 in total

   Run by

   Pfizer

   See if you can join NCT07903415 on ClinicalTrials.gov

4. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD, La Jolla, California

   Locations

   54 in total

   Run by

   Genmab

   See if you can join NCT03526835 on ClinicalTrials.gov

5. Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

   This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT07124351 on ClinicalTrials.gov

6. A Study of MGC030 in Participants With Advanced Solid Tumors

   The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors of select types. The main question the study aims to …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START New York-Long Island, Lake Success, New York

   Run by

   MacroGenics

   See if you can join NCT07822399 on ClinicalTrials.gov

7. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   VA Greater Los Angeles Healthcare System, Los Angeles, California

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

8. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

9. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

   This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI at Florida Cancer Specialists, Orlando, Florida

   Locations

   6 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07807345 on ClinicalTrials.gov

10. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    39 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

11. Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

    This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standar…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Helios CR Inc./RadNet, Cerritos, California

    Locations

    19 in total

    Run by

    SOFIE

    See if you can join NCT07217704 on ClinicalTrials.gov

12. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

    The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Phoenix, Arizona

    Locations

    314 in total

    Run by

    AstraZeneca

    See if you can join NCT07431281 on ClinicalTrials.gov

13. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

14. Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

    This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread …

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    University of Kentucky Markey Cancer Center, Lexington, Kentucky

    Run by

    Mark Bernard

    See if you can join NCT07770100 on ClinicalTrials.gov

15. A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

    The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06123338 on ClinicalTrials.gov

16. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama Birmingham, Birmingham, Alabama

    Locations

    26 in total

    Run by

    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

17. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    31 in total

    Run by

    Pfizer

    See if you can join NCT07090499 on ClinicalTrials.gov

18. Phase 1 Study of PF-08046033 in Advanced Solid Tumors

    This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Presbyterian/St Lukes Medical Center, Denver, Colorado

    Locations

    20 in total

    Run by

    Pfizer

    See if you can join NCT07519655 on ClinicalTrials.gov

19. Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

    Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Harry S Truman Veterans Memorial Hospital, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT03551951 on ClinicalTrials.gov

20. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona

    Locations

    50 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06469944 on ClinicalTrials.gov

21. Distance-Based Exercise to Preserve Function and Prevent Disability

    This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Kaiser Permanente Dublin, Dublin, California

    Locations

    23 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT07059884 on ClinicalTrials.gov

22. A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

    A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 06, Maumee, Ohio

    Locations

    3 in total

    Run by

    TwoStep Therapeutics, Inc.

    See if you can join NCT07814248 on ClinicalTrials.gov

23. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage

    Not phased

    Ages

    18 to 130

    Site

    Research Site, Birmingham, Alabama

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

24. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology, Beverly Hills, California

    Locations

    8 in total

    Run by

    Neonc Technologies, Inc.

    See if you can join NCT06047379 on ClinicalTrials.gov

25. Pan-tumor MRD Study

    The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, f…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Alabama Oncology, Birmingham, Alabama

    Locations

    47 in total

    Run by

    Paradigm Health

    See if you can join NCT06605404 on ClinicalTrials.gov